TP53 and nonpapillary renal cell carcinoma: Intriguingly, several lines of evidence indicated that p53 is rarely mutated in ccRCC (Noon et al., 2012); however, upregulation of wild‐type p53 protein failed to inhibit disease progression or improve the prognosis of ccRCC patients (Mombini et al., 2006; Noon et al., 2010).